Open Access<p>Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons</p>
Author(s) -
John R. Hurst,
Kevin Gruffydd-Jones,
Mousumi Biswas,
Deniz Guranlioglu,
Martin Jenkins,
Neda Stjepanovic,
Arushi Bamrara
Publication year - 2020
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s230955
Subject(s) - medicine , lama , copd , muscarinic antagonist , population , randomized controlled trial , meta analysis , physical therapy , antagonist , receptor , environmental health
This literature review assessed comparative efficacy and safety of long-acting muscarinic antagonist/long-acting β 2 -agonist (LAMA/LABA) fixed-dose combinations (FDCs) in patients with COPD and moderate-to-very severe airflow limitation, using evidence from direct (head-to-head) and indirect treatment comparisons.